alanine has been researched along with rabacfosadine in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (30.77) | 29.6817 |
| 2010's | 5 (38.46) | 24.3611 |
| 2020's | 4 (30.77) | 2.80 |
| Authors | Studies |
|---|---|
| Birkus, G; Chong, L; Cihlar, T; Desai, M; Fridland, A; Henne, IN; Jeraj, R; Lee, WA; Li, B; Liu, X; Plunkett, W; Ray, AS; Reiser, H; Rhodes, GR; Shibata, R; Thamm, DH; Tumas, DB; Vail, D; Wang, J; Watkins, WJ; Wolfgang, GH; Wu, S | 1 |
| Holý, A; Otová, B; Votruba, I | 1 |
| Anderson, C; Babusis, D; Hawkins, MJ; Henne, IN; Jeraj, R; Kurzman, ID; Lawrence, J; Plaza, S; Ray, AS; Reiser, H; Robat, C; Thamm, DH; Tumas, DB; Vail, DM; Vanderhoek, M; Watkins, WJ; Wessel, MA; Wolfgang, GH | 1 |
| Keating, MJ; Plunkett, W; Ray, AS; Reiser, H; Tsai, CY; Tumas, DB | 1 |
| Andrei, G; Cannizzaro, C; Cihlar, T; Fiten, P; Frey, CR; Fung, W; Geleziunas, R; Han, B; Hung, M; Liu, X; Opdenakker, G; Snoeck, R; Votruba, I | 1 |
| Babusis, D; Kurzman, ID; Ray, AS; Sousa-Powers, N; Thamm, DH; Tumas, DB; Vail, DM | 1 |
| Axiak-Bechtel, S; Elmslie, RS; Fan, TM; Klein, MK; Phillips, BS; Post, GS; Ruslander, DA; Thamm, DH; Vail, DM | 1 |
| Burgess, KE; Clifford, CA; Fan, TM; Morges, MA; Phillips, B; Saba, CF; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM | 1 |
| De Clercq, E | 1 |
| Bergman, PJ; Cawley, JR; Clifford, CA; Meleo, K; Post, GS; Thamm, DH; Vail, DM; Vickery, KR; Wright, ZM | 1 |
| Burgess, K; Clifford, C; Curran, K; Elmslie, R; Fan, T; Phillips, B; Post, G; Saba, CF; Thamm, D; Vail, D; Wright, Z | 1 |
| Avery, AC; Bergman, PJ; Christman Hull, AA; Clifford, CA; Donoghue, AR; Gust, CM; McDaniel, JA; Phillips, BS; Post, GS; Randall, EK; Rosenberg, MP; Thamm, DH; Weishaar, KM; Wright, ZM | 1 |
2 review(s) available for alanine and rabacfosadine
| Article | Year |
|---|---|
[Acyclic nucleoside phosphonates as potential antineoplastic agents].
Topics: Adenine; Alanine; Animals; Antineoplastic Agents; Cell Line, Tumor; Guanine; Humans; Lymphoma, Non-Hodgkin; Nucleosides; Organophosphonates; Organophosphorus Compounds; Purines | 2008 |
Tanovea® for the treatment of lymphoma in dogs.
Topics: Alanine; Animals; Antineoplastic Agents; Dogs; Lymphoma; Prodrugs; Purines; Treatment Outcome | 2018 |
3 trial(s) available for alanine and rabacfosadine
| Article | Year |
|---|---|
GS-9219/VDC-1101--a prodrug of the acyclic nucleotide PMEG has antitumor activity in spontaneous canine multiple myeloma.
Topics: Alanine; Animals; Antineoplastic Agents; Cell Line, Tumor; Dog Diseases; Dogs; Female; Guanine; Humans; Male; Multiple Myeloma; Organophosphorus Compounds; Prodrugs; Purines | 2014 |
Rabacfosadine for naïve canine intermediate to large cell lymphoma: Efficacy and adverse event profile across three prospective clinical trials.
Topics: Alanine; Animals; Dog Diseases; Dogs; Female; Lymphoma; Male; Purines; Treatment Outcome | 2020 |
Multicenter, randomized, double-blinded, placebo-controlled study of rabacfosadine in dogs with lymphoma.
Topics: Alanine; Animals; Antineoplastic Combined Chemotherapy Protocols; Dog Diseases; Dogs; Lymphoma; Purines; Treatment Outcome | 2022 |
8 other study(ies) available for alanine and rabacfosadine
| Article | Year |
|---|---|
GS-9219--a novel acyclic nucleotide analogue with potent antineoplastic activity in dogs with spontaneous non-Hodgkin's lymphoma.
Topics: Alanine; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dogs; Guanine; Lymphoid Tissue; Lymphoma, Non-Hodgkin; Organophosphorus Compounds; Prodrugs; Purines; Tissue Distribution | 2008 |
Assessment of GS-9219 in a pet dog model of non-Hodgkin's lymphoma.
Topics: Alanine; Animals; Animals, Domestic; Anorexia; Antineoplastic Agents; Area Under Curve; Diarrhea; Dideoxynucleosides; Disease Models, Animal; Dog Diseases; Dogs; Drug Administration Schedule; Female; Humans; Kaplan-Meier Estimate; Lymphoma, Non-Hodgkin; Male; Metabolic Clearance Rate; Nausea; Positron-Emission Tomography; Purines; Tissue Distribution; Tomography, X-Ray Computed; Treatment Outcome; Weight Loss | 2009 |
Targeting DNA repair in chronic lymphocytic leukemia cells with a novel acyclic nucleotide analogue, GS-9219.
Topics: Alanine; Apoptosis; Apoptosis Regulatory Proteins; bcl-2-Associated X Protein; Cell Survival; Chromatography, High Pressure Liquid; DNA Damage; DNA Repair; DNA, Neoplasm; Dose-Response Relationship, Drug; Guanine; Humans; Immunoblotting; Leukemia, Lymphocytic, Chronic, B-Cell; Models, Biological; Molecular Structure; Organophosphorus Compounds; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-bcl-2; Purines; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Tumor Cells, Cultured; Ultraviolet Rays | 2009 |
Mutations in adenosine deaminase-like (ADAL) protein confer resistance to the antiproliferative agents N6-cyclopropyl-PMEDAP and GS-9219.
Topics: Adenine; Alanine; Amino Acid Sequence; Antineoplastic Agents; Blotting, Western; Drug Resistance, Neoplasm; Female; Humans; Molecular Sequence Data; Mutation; Nucleoside Deaminases; Prodrugs; Protein Conformation; Purines; Sequence Homology, Amino Acid; Tumor Cells, Cultured; Uterine Cervical Neoplasms | 2013 |
Alternating Rabacfosadine/Doxorubicin: Efficacy and Tolerability in Naïve Canine Multicentric Lymphoma.
Topics: Alanine; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Doxorubicin; Drug Administration Schedule; Female; Lymphoma; Male; Prodrugs; Purines; Treatment Outcome | 2017 |
Rabacfosadine for relapsed canine B-cell lymphoma: Efficacy and adverse event profiles of 2 different doses.
Topics: Alanine; Animals; Antineoplastic Agents; Dog Diseases; Dogs; Dose-Response Relationship, Drug; Lymphoma, B-Cell; Purines; Recurrence; Treatment Outcome | 2018 |
Concurrent use of rabacfosadine and L-asparaginase for relapsed or refractory multicentric lymphoma in dogs.
Topics: Alanine; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Colorado; Disease-Free Survival; Dog Diseases; Dogs; Female; Lymphoma; Male; Neoplasm Recurrence, Local; Prospective Studies; Purines; Remission Induction; Washington; Wisconsin | 2020 |
Topics: Alanine; Animals; Dog Diseases; Dogs; Lymphoma; Purines | 2022 |